Press Releases

GlobeNewswire, Inc.

– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells1 provides new insights into simufilam’s potential mechanism of action...

EIN Presswire

DALLAS, TX, UNITED STATES, November 5, 2026 /⁨EINPresswire.com⁩/ -- The National Financial Educators Council (NFEC) is launching its Caribbean chapter to support financial educators, strengthen local programmes, and connect organisations committed...

GlobeNewswire, Inc.

– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS® Quarterly Net Revenue of $26.5 Million in First...

GlobeNewswire, Inc.

Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026 Received FDA Fast Track designation for SAB-142 in...

GlobeNewswire, Inc.

Third Quarter Revenue of $42.7 Million, Up 12% Year-over-Year Exchange Revenue Grew 24% Year-over-Year to $25.5 Million Adjusted EBITDA of $1.1 Million vs $0.2 Million in the Prior Year (All monetary figures are expressed in Canadian dollars...

GlobeNewswire, Inc.

FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027 QTORIN™ Rapamycin Could Become the First FDA-Approved Therapy for Microcystic Lymphatic...

GlobeNewswire, Inc.

RESET-Myositis® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data Immunomodulator-free...

GlobeNewswire, Inc.

- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 - - Additional one-year clinical data from Phase 1/2 ACHIEVE trial of...

GlobeNewswire, Inc.

Revenue was $809 million, up 5.3%, and up 7.4% on an organic constant currency (OCC) basis, a non-GAAP measure.

GlobeNewswire, Inc.

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Teads Holding Co. (Nasdaq: TEAD), the omnichannel outcomes platform (the “Company” or “Teads”), today announced the appointment of Michael Coyle as Chief Financial Officer, effective November 11, 2026....

GlobeNewswire, Inc.

Declares Regular Quarterly Dividend Board Authorizes $20M Share Repurchase Program GARDEN CITY, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and marketer of a broad range of...

GlobeNewswire, Inc.

Third Consecutive Quarter with Year-over-Year Revenue Growth GAAP Net Cash Provided by Operating Activities was $146 million, an increase of $74 million or 103% year-over-year.

GlobeNewswire, Inc.

Quarterly net revenues of $290.8 million, an increase of 27.6% year-over-year Purified Cortrophin® Gel net revenues of $138.7 million, an increase of 36.1% year-over-year Quarterly GAAP net income available to common shareholders of $35.1 million;...

GlobeNewswire, Inc.

RENO, Nev., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in lithium battery technology, today announced that the Company will release its financial and...

GlobeNewswire, Inc.

Third quarter milestones included a definitive power agreement that removes approximately $33 million of upfront costs from the construction budget and enactment of new Brazilian legislation, Profert, favorable to the Company Front End Engineering...

GlobeNewswire, Inc.

Q3 2026 EPS Exceeded the Guidance, Both Revenue and GM In-Line With Guidance Issued on Aug. 6, 2026 Company Q4 2026 Guidance: Revenues to Decrease 22% to 26%, Gross Margin is Expected to be Flat to Slightly up. Profit per Diluted ADS to be 4.5...

GlobeNewswire, Inc.

Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose levels, with treatment-emergent adverse event rates...

GlobeNewswire, Inc.

Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027...

GlobeNewswire, Inc.

CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing Initiated dosing in NAVIGATE-2 Phase 2 trial of CLYM116 in IgAN;...

GlobeNewswire, Inc.

Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025 Q3 2026 Vafseo® (vadadustat) net product revenues of $14.8 million, impacted by...